First results of UK national medicine use review audit show benefit of MURs

16 February 2010

In the UK, 80% of the patients who took part in the first audit of Medicine Use Reviews (MUR) said their knowledge on medicines and how to use them had improved because of an MUR. The service consists of accredited pharmacists undertaking structured concordance centered reviews with patients on multiple medicines, particularly those receiving drugs for long term conditions.

The MUR process attempts to establish a picture of the patient's use of their medicines - both prescribed and non-prescribed. The review it aimed to help patients understand their therapy and it will identify any problems they are experiencing along with possible solutions. A report of the review is provided to patients and to their general practitioner.

This was just one of the new findings following a national on-line audit which launched six months ago so that Primary Care Organizations (PCOs) and pharmacists could review the MUR patient service.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >